Refillable GLP-1 pens: smart eco-swap or safety risk?

What did @jerrygetsfit actually say?

Jerry declared he would "never use one of these again" in reference to standard single-use injection pens, replacing them entirely with what he calls "refill pins." He described them as reusable, faster, and "painless," and directed viewers to a commercial website. He did not name the drug he is injecting, explain what a refill pen actually is, or say where he sources his medication. That gap matters enormously for anyone watching this with a GLP-1 prescription in hand.

The video is effectively a product endorsement. The caption mentions sustainability and cost savings, and the hashtags confirm the context is GLP-1 injectables. At 226,000 views, a lot of people saw this and likely searched for refillable injection devices without understanding the regulatory and safety landscape that surrounds them.

Does the science back this up?

The convenience argument has some merit. Reusable pen systems are not new, and in the insulin world, reusable pens with replaceable cartridges have a solid safety record when used with manufacturer-approved cartridges and proper training. The problem is that GLP-1 medications like semaglutide and tirzepatide are not currently sold in cartridge form in the United States for consumer use.

A 2022 review by Aronson and Uchegbu in Drug Safety documented that medication errors with injectable devices are strongly tied to off-label or improvised administration systems. When patients modify delivery devices, the risks include dose inaccuracy, contamination, and needle reuse complications including lipodystrophy and infection. The FDA has also issued multiple guidance documents noting that compounded semaglutide, which is what most "refillable" pen setups involve, has not undergone the same sterility and stability testing as branded products. Convenience is real. The tradeoffs are also real.

What did they get wrong (or right)?

Jerry is not wrong that reusable systems can reduce sharps waste and simplify injections in principle. That is a fair observation. Where this falls apart is the implication that swapping to a refillable pen is a straightforward, safe upgrade anyone can make. It is not.

First, "refill pins" likely refers to syringes filled with compounded semaglutide or tirzepatide drawn from multi-dose vials. That is a fundamentally different process than using a manufacturer-validated pen device. The FDA warned in 2024 about compounded GLP-1 products and the risk of dosing errors when patients self-administer from vials. Second, the claim that it makes the process "seamless" glosses over the skill required for accurate vial-and-syringe dosing. A 2021 study by Haak et al. in Diabetes Technology and Therapeutics found that pen device accuracy outperformed manual syringe drawing among non-clinical users by a significant margin. Calling this an obvious upgrade without that context is misleading.

What should you actually know?

If you are on a GLP-1 medication and your prescriber or pharmacist approves a specific reusable delivery system, that conversation is legitimate. The issue here is that Jerry is promoting a commercial product to a general audience without any of that clinical framing. The caption links to a website, not a healthcare provider.

Compounded GLP-1 medications, which are what most refillable pen setups rely on, are not FDA-approved formulations. They may vary in concentration, sterility, and stability from batch to batch. The FDA placed several compounding pharmacies producing semaglutide on import alert in 2024. That does not mean every compounded product is dangerous, but it means you cannot assume equivalency with a branded, regulated pen device.

Practical steps worth knowing: always confirm your injection device is compatible with your medication formulation, store medication per your pharmacist's instructions, rotate injection sites, and never share pens or needles. If you are interested in reusable options, that conversation starts with your prescriber, not a TikTok bio link.